查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800999

2025-2033年医院感染治疗市场报告（依药物类型、适应症及地区）

Hospital Infection Therapeutics Market Report by Drug Type, Indication, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球医院感染治疗市场规模达131亿美元。展望未来， IMARC Group预计到2033年，该市场规模将达到196亿美元，2025-2033年期间的复合年增长率（CAGR）为4.32%。多重抗药性感染发病率的不断上升、对抗菌药物管理的日益重视、研发的持续进步以及全球医疗支出和基础设施建设的不断增加，是影响市场成长的一些关键因素。

医院感染治疗市场趋势：

院内感染（HAI）发生率不断上升：

医院感染治疗市场的主要驱动因素之一是医院感染（HAI）发生率的上升。这些感染可能由细菌、病毒或真菌引起，通常与侵入性医疗操作、手术或医疗器械的使用有关。 HAI的流行是全球关注的重大问题，导致对有效疗法的需求日益增长，以控制和治疗这些感染。此外，抗药性病原体在医疗机构内的蔓延进一步加剧了对先进且有针对性的治疗方案的需求，因此有必要开发创新且有效的疗法来有效对抗这些感染。

抗菌药物管理计划意识不断增强

抗菌药物管理计画已成为对抗抗菌药物抗药性出现和蔓延的关键策略，并日益受到重视。这些项目致力于优化抗菌药物的使用，以改善患者预后，同时最大限度地减少抗药性的产生。抗菌药物管理意识的不断增强，促使人们更加重视开发和采用能够应对抗药性病原体所带来具体挑战的新型疗法，这为市场扩张创造了积极的前景。此外，全球各地的各类医疗保健组织和监管机构正在积极推广抗菌药物管理，以确保合理使用抗生素和其他抗菌药物，从而推动市场成长。

研发活动取得重大进展

传染病领域持续进行的研发活动大大促进了医院感染治疗市场的扩张。同时，基因组学、微生物学和免疫学的进步为理解感染机制和识别新型药物标靶提供了宝贵的见解。新型抗菌化合物的发现和联合疗法的开发也有助于市场扩张。此外，製药公司、学术机构和研究组织之间的广泛合作推动了创新治疗方式的发现和开发，包括单株抗体、疫苗和新型抗生素，从而推动了市场的成长。

医疗支出增加和基础设施发展

全球医疗支出的成长以及医疗产业基础设施的持续发展，推动了医院感染治疗市场的成长。同时，许多政府和私人投资者正在投资扩大和现代化医疗设施，包括医院和诊所。这反过来又推动了对感染治疗的需求，使医疗保健提供者能够获得有效的工具来管理和控制医院感染的发生率，从而促进了市场的成长。此外，新兴经济体医疗基础设施的扩张也为医院感染治疗开闢了新的市场。随着医疗服务可近性的改善，对先进治疗方案的需求激增，以应对与传染病相关的医疗挑战。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球医院感染治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依药物类型

  • 抗菌药物
  • 抗真菌药物
  • 抗病毒药物
  • 其他的

第七章：市场区隔：依指标

  • 血流感染
  • 泌尿道感染
  • 手术部位感染
  • 肺炎
  • 其他的

第八章：市场区隔：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第九章：SWOT分析

第 10 章：价值链分析

第 11 章：波特五力分析

第 12 章：价格分析

第 13 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Allergan Plc (AbbVie Inc.)
    • AstraZeneca Plc
    • Bayer Aktiengesellschaft
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG (Roche Holding AG)
    • Gilead Sciences Inc.
    • GlaxoSmithKline Plc
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112025A2393

The global hospital infection therapeutics market size reached USD 13.1 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 19.6 Billion by 2033, exhibiting a growth rate (CAGR) of 4.32% during 2025-2033. The escalating incidence of multidrug-resistant infections, a growing emphasis on antimicrobial stewardship, continuous advancements in research and development (R&D), and increased healthcare expenditure and infrastructure development worldwide represent some of the key factors influencing the market growth.

Hospital Infection Therapeutics Market Trends:

Increasing incidence of hospital-acquired infections (HAIs):

One of the primary drivers of the hospital infection therapeutics market is the rising incidence of HAIs. These infections can be bacterial, viral, or fungal in nature and are often associated with invasive medical procedures, surgeries, or the use of medical devices. The prevalence of HAIs is a major concern globally, leading to an increased demand for effective therapeutics to manage and treat these infections. Besides this, the spread of drug-resistant pathogens within healthcare settings has further intensified the need for advanced and targeted treatment options, necessitating the development of innovative and potent therapeutics to combat these infections effectively.

Growing awareness of antimicrobial stewardship programs

Antimicrobial stewardship programs have gained prominence as a key strategy to combat the emergence and spread of antimicrobial resistance. These programs focus on optimizing the use of antimicrobial agents to improve patient outcomes while minimizing the development of resistance. The growing awareness of antimicrobial stewardship has led to an increased emphasis on the development and adoption of novel therapeutics that can address the specific challenges posed by drug-resistant pathogens, creating a positive outlook for market expansion. Moreover, various healthcare organizations and regulatory bodies across the globe are actively promoting antimicrobial stewardship to ensure the judicious use of antibiotics and other antimicrobial agents are providing an impetus to the market growth.

Significant advancements in R&D activities

Ongoing R&D activities in the field of infectious diseases have contributed significantly to the expansion of the hospital infection therapeutics market. In line with this, advancements in genomics, microbiology, and immunology have provided valuable insights into the mechanisms of infection and the identification of novel drug targets. The discovery of new antimicrobial compounds and the development of combination therapies are aiding in market expansion. In addition to this, extensive collaborations between pharmaceutical companies, academic institutions, and research organizations have propelled the discovery and development of innovative therapeutic modalities, including monoclonal antibodies, vaccines, and novel antibiotics, thereby impelling the market growth.

Rising healthcare expenditure and infrastructure development

The global increase in healthcare expenditure and ongoing infrastructure development in the healthcare sector are fueling the growth of the hospital infection therapeutics market. Concurrent with this, numerous governments and private investors are investing in the expansion and modernization of healthcare facilities, including hospitals and clinics. This, in turn, drives the demand for infection therapeutics to equip healthcare providers with effective tools to manage and control the incidence of HAIs, thus bolstering the market growth. Furthermore, the expansion of healthcare infrastructure in emerging economies has opened up new markets for hospital infection therapeutics. As healthcare access improves, there is a surging demand for advanced treatment options to address the healthcare challenges associated with infectious diseases.

Hospital Infection Therapeutics Industry Segmentation:

Breakup by Drug Type:

  • Anti-bacterial Drugs
  • Anti-fungal Drugs
  • Anti-viral Drugs
  • Others

Anti-bacterial drugs accounts for the majority of the market share

The rising demand for anti-bacterial hospital infection therapeutics driven by the escalating threat of multidrug-resistant bacteria, necessitating the development of effective antibiotics to combat evolving bacterial strains is fostering market expansion.

In confluence with this, the increasing prevalence of invasive fungal infections, particularly in immunocompromised patients, is propelling the demand for anti-fungal drugs, addressing the unique challenges posed by fungal hospital-acquired infections.

Additionally, the expanding demand for targeted anti-viral hospital infection therapeutics due to the persistent threat of viral outbreaks, such as influenza and emerging viruses is acting as another significant growth-inducing factor.

Diverse infectious agents and evolving resistance patterns spurring the demand for innovative therapeutics beyond conventional categories and leading to the development of alternative drugs to address specific hospital infection challenges are presenting lucrative opportunities for market expansion.

Breakup by Indication:

  • Blood Stream Infections
  • Urinary Tract Infections
  • Surgical Site Infections
  • Pneumonia
  • Others

Surgical site infections holds the largest share of the industry

The escalating concerns about surgical site infections due to the risk they pose to postoperative recovery are bolstering the need for specialized drugs to prevent and manage infections at surgical sites, thereby propelling the market forward.

The critical nature of blood stream infections, necessitating effective treatments to prevent systemic complications and improve patient outcomes is contributing to the increasing demand and sales of hospital infection therapeutics.

Concurrently, the rising incidences of urinary tract infections (UTIs) are further boosting the demand for therapeutics, with a focus on addressing the specific challenges associated with UTIs, including recurrent infections and antibiotic resistance.

Moreover, the increasing complexity associated with respiratory infections like pneumonia is also fostering the demand for effective hospital infection therapeutics to combat bacterial, viral, and fungal pneumonia, ensuring optimal patient care.

Apart from this, growing cases of skin and soft tissue infections, gastrointestinal infections, and respiratory tract infections driving the demand for specialized hospital infection therapeutics are influencing market expansion.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Europe leads the market, accounting for the largest hospital infection therapeutics market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, Europe accounted for the largest market share.

The rising awareness of infectious diseases, well-established healthcare systems, and a proactive approach to antimicrobial stewardship in Europe leading to a continuous need for advanced therapeutics are contributing to the market expansion.

Moreover, North America's robust healthcare infrastructure, stringent regulatory frameworks, and a high prevalence of healthcare-associated infections necessitating effective treatment solutions are positively impacting the market growth.

Furthermore, extensive healthcare investments, a growing burden of infectious diseases, and a surge in hospital infrastructure development in the Asia Pacific are creating remunerative opportunities for the expansion of the hospital infection therapeutics market.

Besides this, Latin America's evolving healthcare policies and supportive efforts aimed at enhancing healthcare accessibility while expanding healthcare infrastructure and a rising focus on healthcare quality in the Middle East and Africa emphasizing the need for advanced hospital infection therapeutics are propelling the market growth.

Leading Key Players in the Hospital Infection Therapeutics Industry:

The global hospital infection therapeutics market is characterized by intense competition among pharmaceutical companies striving to address the increasing prevalence of hospital-acquired infections. Key players in the market are engaged in extensive R&D activities to introduce innovative therapeutics, ranging from antibiotics to antiviral drugs, tailored to combat multidrug-resistant pathogens. Strategic collaborations and partnerships between industry players, academic institutions, and research organizations are commonplace, fostering the exchange of knowledge and expertise. The emphasis on antimicrobial stewardship programs further shapes the competitive landscape, with companies working to align their products with principles promoting the judicious use of antimicrobial agents. Regulatory compliance, market penetration strategies, and a focus on addressing specific indications within the hospital infection spectrum are pivotal factors influencing the competitive dynamics of this dynamic and evolving market.

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Allergan Plc (AbbVie Inc.)
  • AstraZeneca Plc
  • Bayer Aktiengesellschaft
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG (Roche Holding AG)
  • Gilead Sciences Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc
  • Pfizer Inc.
  • Sanofi S.A.

Key Questions Answered in This Report:

  • How has the global hospital infection therapeutics market performed so far, and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global hospital infection therapeutics market?
  • What is the impact of each driver, restraint, and opportunity on the global hospital infection therapeutics market?
  • What are the key regional markets?
  • Which countries represent the most attractive hospital infection therapeutics market?
  • What is the breakup of the market based on the drug type?
  • Which is the most attractive drug type in the hospital infection therapeutics market?
  • What is the breakup of the market based on the indication?
  • Which is the most attractive indication in the hospital infection therapeutics market?
  • What is the competitive structure of the market?
  • Who are the key players/companies in the global hospital infection therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hospital Infection Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Anti-bacterial Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Anti-fungal Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Anti-viral Drugs
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Blood Stream Infections
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Urinary Tract Infections
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Surgical Site Infections
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Pneumonia
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Allergan Plc (AbbVie Inc.)
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Bayer Aktiengesellschaft
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Bristol-Myers Squibb Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 SWOT Analysis
    • 13.3.6 Gilead Sciences Inc.
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 GlaxoSmithKline Plc
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Johnson & Johnson
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hospital Infection Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Hospital Infection Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Hospital Infection Therapeutics Market: Breakup by Drug Type (in %), 2024
  • Figure 4: Global: Hospital Infection Therapeutics Market: Breakup by Indication (in %), 2024
  • Figure 5: Global: Hospital Infection Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 6: Global: Hospital Infection Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 7: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Hospital Infection Therapeutics (Anti-bacterial Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Hospital Infection Therapeutics (Anti-fungal Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Hospital Infection Therapeutics (Anti-viral Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Hospital Infection Therapeutics (Other Drug Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Hospital Infection Therapeutics (Other Drug Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Hospital Infection Therapeutics (Blood Stream Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Hospital Infection Therapeutics (Urinary Tract Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Hospital Infection Therapeutics (Surgical Site Infections) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Hospital Infection Therapeutics (Pneumonia) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Hospital Infection Therapeutics (Pneumonia) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Hospital Infection Therapeutics (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Hospital Infection Therapeutics (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: North America: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: North America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: United States: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: United States: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Canada: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Canada: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Asia Pacific: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Asia Pacific: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: China: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: China: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Japan: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Japan: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: India: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: India: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: South Korea: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: South Korea: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Australia: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Australia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Indonesia: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Indonesia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Others: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Europe: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Europe: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Germany: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Germany: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: France: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: France: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: United Kingdom: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: United Kingdom: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Italy: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Italy: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Spain: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Spain: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Russia: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Russia: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Latin America: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Latin America: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Brazil: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Brazil: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Mexico: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Mexico: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Others: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Others: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Middle East and Africa: Hospital Infection Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Middle East and Africa: Hospital Infection Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Global: Hospital Infection Therapeutics Industry: SWOT Analysis
  • Figure 74: Global: Hospital Infection Therapeutics Industry: Value Chain Analysis
  • Figure 75: Global: Hospital Infection Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hospital Infection Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 3: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 4: Global: Hospital Infection Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Hospital Infection Therapeutics Market Structure
  • Table 6: Global: Hospital Infection Therapeutics Market: Key Players